Carfilzomib, Dexamethasone, And Daratumumab Versus Carfilzomib And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma (Candor): Results From A Randomised, Multicentre, Open-Label, Phase 3 Study(Vol 396, 186, 2020)
LANCET（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要